drugset / Trial / NCT00407043
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Phase 4
Completed
5 enrolled
Ophthalmic Consultants of Long Island
Bausch & Lomb Incorporated · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
Timeline
- Start
- 2006-11
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loteprednol Etabonate | Other / unclassified | 0.5 % | — |
| Background | Cyclosporine | Peptide | 0.05 % | Topical |